Nanobiotix (NBTX) Competitors

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nanobiotix presently has a consensus target price of $37.33, indicating a potential downside of 2.78%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 7.31%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than Lantheus.

In the previous week, Lantheus had 4 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Lantheus and 0 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.00 beat Lantheus' score of -0.48 indicating that Nanobiotix is being referred to more favorably in the media.

Lantheus has higher revenue and earnings than Nanobiotix.

Nanobiotix has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Nanobiotix has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Nanobiotix's return on equity of 0.00% beat PTC Therapeutics' return on equity.

PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, PTC Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 9 mentions for PTC Therapeutics and 0 mentions for Nanobiotix. PTC Therapeutics' average media sentiment score of 1.07 beat Nanobiotix's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media.

PTC Therapeutics has higher revenue and earnings than Nanobiotix.

PTC Therapeutics presently has a consensus price target of $91.36, indicating a potential upside of 9.66%. Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 2.78%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Nanobiotix.

38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Nanobiotix presently has a consensus price target of $37.33, indicating a potential downside of 2.78%. Mirum Pharmaceuticals has a consensus price target of $143.00, indicating a potential upside of 13.86%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Nanobiotix.

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 0 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 0.82 beat Nanobiotix's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Nanobiotix has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Nanobiotix has higher revenue and earnings than Centessa Pharmaceuticals.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nanobiotix's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Nanobiotix. MarketBeat recorded 1 mentions for Centessa Pharmaceuticals and 0 mentions for Nanobiotix. Centessa Pharmaceuticals' average media sentiment score of 0.00 equaled Nanobiotix'saverage media sentiment score.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Centessa Pharmaceuticals presently has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Nanobiotix has a consensus price target of $37.33, suggesting a potential downside of 2.78%. Given Centessa Pharmaceuticals' higher possible upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Nanobiotix.